RU2002123286A - FILLED PROTEIN WITH INCREASED ERYTHROPOETHIN ACTIVITY, NUCLEIC ACID ENCODING FULL PROTEIN, AND METHOD FOR PRODUCING FUSED PROTEIN - Google Patents

FILLED PROTEIN WITH INCREASED ERYTHROPOETHIN ACTIVITY, NUCLEIC ACID ENCODING FULL PROTEIN, AND METHOD FOR PRODUCING FUSED PROTEIN

Info

Publication number
RU2002123286A
RU2002123286A RU2002123286/13A RU2002123286A RU2002123286A RU 2002123286 A RU2002123286 A RU 2002123286A RU 2002123286/13 A RU2002123286/13 A RU 2002123286/13A RU 2002123286 A RU2002123286 A RU 2002123286A RU 2002123286 A RU2002123286 A RU 2002123286A
Authority
RU
Russia
Prior art keywords
protein
fusion protein
nucleic acid
acid encoding
activity
Prior art date
Application number
RU2002123286/13A
Other languages
Russian (ru)
Other versions
RU2232192C2 (en
Inventor
Донг-еок ЛИ
Мьюнг-сук ОХ
Ки-Ван КИМ
Бо-Суп ЧУНГ
Джи-соок ПАРК
Original Assignee
Чеил Джеданг Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-2001-0075994A external-priority patent/KR100467751B1/en
Application filed by Чеил Джеданг Корпорейшн filed Critical Чеил Джеданг Корпорейшн
Publication of RU2002123286A publication Critical patent/RU2002123286A/en
Application granted granted Critical
Publication of RU2232192C2 publication Critical patent/RU2232192C2/en

Links

Claims (6)

1. Слитый белок, включающий эритропоэтин (ЕРО) человека, имеющий С-конец, и мутант, связанный с этим С-концом, причем указанный мутант является фрагментом С-концевого пептида (СТР) β-субъединицы хорионического гонадотропина человека (HCG) с одной-четырьмя аминокислотными заменами в этом фрагменте СТР.1. A fusion protein comprising human erythropoietin (EPO) having a C-terminus and a mutant linked to this C-terminus, said mutant being a fragment of the C-terminal peptide (CTP) of human β-subunit of human chorionic gonadotropin (HCG) with one - four amino acid substitutions in this CTP fragment. 2. Слитый белок по п.1, отличающийся тем, что фрагмент СТР включает все аминокислоты или некоторые из аминокислот, соответствующие положениям 112-145 β-субъединицы HCG, причем эта последовательность приведена в SEQ ID NO:1.2. The fusion protein according to claim 1, characterized in that the CTP fragment includes all amino acids or some of the amino acids corresponding to the positions 112-145 of the β-subunit of HCG, and this sequence is shown in SEQ ID NO: 1. 3. Слитый белок по п.2, отличающийся тем, что мутант имеет одну или несколько замен в положениях 121, 127, 132 и 138 β-субъединицы HCG.3. The fusion protein according to claim 2, characterized in that the mutant has one or more substitutions at positions 121, 127, 132 and 138 of the β-subunit of HCG. 4. Слитый белок по п.3, отличающийся тем, что в мутанте остатки серина в положениях 121, 127, 132 и 138 β-субъединицы HCG заменены аланином или глицином.4. The fusion protein according to claim 3, characterized in that in the mutant the serine residues at positions 121, 127, 132 and 138 of the HCG β-subunit are replaced by alanine or glycine. 5. Нуклеиновая кислота, кодирующая слитый белок по любому из пп.1-4.5. A nucleic acid encoding a fusion protein according to any one of claims 1 to 4. 6. Способ получения слитого белка, имеющего увеличенную активность ЕРО in vivo, включающий культивирование клеточной линии, трансфицированной рекомбинантным вектором, содержащим нуклеиновую кислоту по п.5.6. A method of producing a fusion protein having increased EPO activity in vivo, comprising culturing a cell line transfected with a recombinant vector containing a nucleic acid according to claim 5.
RU2002123286/13A 2001-12-03 2002-08-29 Fused protein with enhanced erythropoietin activity, nucleic acid encoding fused protein and method for preparing fused protein RU2232192C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR2001-0075994 2001-12-03
KR10-2001-0075994A KR100467751B1 (en) 2001-12-03 2001-12-03 Fusion protein having the enhanced in vivo erythropoietin activity

Publications (2)

Publication Number Publication Date
RU2002123286A true RU2002123286A (en) 2004-04-20
RU2232192C2 RU2232192C2 (en) 2004-07-10

Family

ID=36123483

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002123286/13A RU2232192C2 (en) 2001-12-03 2002-08-29 Fused protein with enhanced erythropoietin activity, nucleic acid encoding fused protein and method for preparing fused protein

Country Status (17)

Country Link
US (1) US7091326B2 (en)
EP (1) EP1316561B1 (en)
JP (1) JP4035400B2 (en)
KR (1) KR100467751B1 (en)
CN (1) CN100400548C (en)
AT (1) ATE352565T1 (en)
AU (1) AU2002300734B2 (en)
BR (1) BR0203386A (en)
CA (1) CA2400908C (en)
DE (1) DE60217804T2 (en)
ES (1) ES2280487T3 (en)
MX (1) MXPA02008454A (en)
NZ (1) NZ520776A (en)
RU (1) RU2232192C2 (en)
TW (1) TWI243827B (en)
WO (1) WO2003048210A1 (en)
ZA (1) ZA200206879B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
ZA200603396B (en) * 2003-09-29 2007-11-28 Warren Pharmaceuticals Inc Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
CN100516225C (en) * 2004-07-30 2009-07-22 成都地奥制药集团有限公司 Interfusion protein of human serum protein and erythropoietin
NZ565937A (en) * 2005-08-05 2011-09-30 Araim Pharmaceuticals Inc Tissue protective peptides and uses thereof
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US7553941B2 (en) * 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
CN100436482C (en) * 2006-04-14 2008-11-26 东莞太力生物工程有限公司 Long effective amalgamation protein of erythropoietin of human, preparing and purifying methods
BRPI0814465B1 (en) 2007-07-26 2021-11-23 Novagen Holding Corporation FUSION PROTEIN, DIMER, METHOD FOR PRODUCING A FUSION PROTEIN, CELL LINEAGE, USES OF A FUSION PROTEIN AND A PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
CN102994547B (en) * 2011-09-08 2015-05-13 哈药集团技术中心 Recombinant human erythropoietin-CTP fusion protein production process and application
CN103182073A (en) * 2011-12-29 2013-07-03 哈药集团技术中心 Pharmaceutical injection of recombinant human interferon alpha-CTP fusion protein
SG11201406671RA (en) 2012-04-19 2014-11-27 Opko Biolog Ltd Long-acting oxyntomodulin variants and methods of producing same
MY172997A (en) * 2012-11-20 2019-12-18 Opko Biologics Ltd Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP4212546A1 (en) * 2014-12-10 2023-07-19 OPKO Biologics Ltd. Methods of producing long acting ctp-modified polypeptides
IL301728A (en) 2015-06-19 2023-05-01 Opko Biologics Ltd Long-acting coagulation factors and methods of producing same
BR112019000610A2 (en) 2016-07-11 2019-07-02 Opko Biologics Ltd long-acting coagulation factor vii and production methods thereof
CN110393801A (en) * 2018-04-24 2019-11-01 中国科学院上海生命科学研究院 Target the application that interstitialcellstimulating hormone (ICSH) promotes body hematopoiesis
CN112175088B (en) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 FIX fusion proteins, conjugates and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225449B1 (en) * 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
EP0461200B1 (en) * 1989-02-21 1997-01-22 Washington University Modified forms of reproductive hormones
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
ES2141229T3 (en) * 1993-04-20 2000-03-16 Univ Washington PHARMACEUTICAL PRODUCTS OF MODIFIED PROTEINS AND PEPTIDES.
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
CZ299516B6 (en) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof
PE20010288A1 (en) * 1999-07-02 2001-03-07 Hoffmann La Roche ERYTHROPOYETIN DERIVATIVES
JP4944324B2 (en) 1999-07-13 2012-05-30 ボルダー バイオテクノロジー， インコーポレイテッド Immunoglobulin fusion protein
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
WO2002048194A1 (en) 2000-12-11 2002-06-20 Cheil Jedang Corporation Fusion protein having the enhanced in vivo activity of erythropoietin

Similar Documents

Publication Publication Date Title
RU2002123286A (en) FILLED PROTEIN WITH INCREASED ERYTHROPOETHIN ACTIVITY, NUCLEIC ACID ENCODING FULL PROTEIN, AND METHOD FOR PRODUCING FUSED PROTEIN
CA2400908A1 (en) Fusion protein having enhanced in vivo erythropoietin activity
RU2002123438A (en) FUSION PROTEIN POSSESSING IN VIVO ENHANCED ERYTHROPOETIN ACTIVITY
ATE421977T1 (en) PURIFICATION OF PEPTIDES USING METAL-ION AFFINITY CHROMATOGRAPHY
NZ503850A (en) April - a novel protein with growth effects
CA2443365A1 (en) Methods for the recombinant production of antifusogenic peptides
NZ504548A (en) Polypeptides and nucleic acids encoding human chordin
NZ597685A (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
CA2289912A1 (en) Human receptor proteins; related reagents and methods
NO965411L (en) N-terminally extended proteins expressed in yeast
NZ502391A (en) Mammalian cytokine: interleukin-B30 and related reagents
EP1342730A4 (en) Fusion protein having the enhanced in vivo activity of erythropoietin
WO1999050282A3 (en) Peptides for the treatment, prophylaxis, diagnosis and monitoring of autoimmune diseases
RU93045577A (en) MULTIPLE POLYPEPTIDES
WO1999005270A3 (en) Crustacean antimicrobial peptides, called penaiedines
CA2324513A1 (en) Chimeric protein containing an intramolecular chaperone-like sequence and its application to insulin production
NZ527971A (en) Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
JP2004505601A5 (en)
DE69935599D1 (en) MODIFIED HCV PEPTIDE VACCINES
MY135991A (en) A vaccine-induced hepatits b viral strain and uses thereof
SG109959A1 (en) 5-substituted hydantoin recemase, dna coding for the same, recombinant dna, transformed cells, and process for producing optically active amino acids
KR970065554A (en) Cleavage of chimeric proteins using processing enzymes
EP1065214A4 (en) Novel physiologically active peptides and utilization thereof
ES2072422T3 (en) PROCEDURE FOR THE PRODUCTION OF FRIENDLY PEPTIDES IN ALPHA IN TERMINAL C.
KR930000684A (en) Cloned Glutamate Decarboxylase